Clinical Trials Browser

Interventional × Chondrosarcoma × 90 days × Clear all

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

NCT04278781 2026-04-23

AG-120 in People With IDH1 Mutant Chondrosarcoma

Phase 2 Active not recruiting

6 enrolled

LymphoidSarcoma

Chondrosarcoma, Lymphoma, Follicular

NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Phase 1 Active not recruiting

200 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT05039801 2026-04-15

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Phase 1 Recruiting

54 enrolled

DermatologicGynecologicHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Chondrosarcoma, Melanoma, Ovarian Neoplasms, Endometrial Neoplasms

NCT01267955 2026-04-13

Vismodegib in Treating Patients With Advanced Chondrosarcomas

Phase 2 Active not recruiting

45 enrolled 10 charts

Sarcoma

Chondrosarcoma, Clear Cell, Chondrosarcoma, Chondrosarcoma, Mesenchymal

NCT00496522 2026-03-09

Proton Beam Therapy for Chondrosarcoma

Phase 2 Active not recruiting

15 enrolled

Sarcoma

Chondrosarcoma

Clinical Trials

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

AG-120 in People With IDH1 Mutant Chondrosarcoma

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Vismodegib in Treating Patients With Advanced Chondrosarcomas

Proton Beam Therapy for Chondrosarcoma